European Journal of Cancer and Clinical Oncology最新文献

{"title":"Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer","authors":"Vernon J. Harvey ,&nbsp;Janet R. Hardy ,&nbsp;Shelba Smith ,&nbsp;William Grove ,&nbsp;Bruce C. Baguley","doi":"10.1016/0277-5379(91)90427-F","DOIUrl":"10.1016/0277-5379(91)90427-F","url":null,"abstract":"<div><p>CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino]-N,5-dimethyl-4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m² divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade ≥ 3 was seen in 15 patients, infections with recovery in 3, and <em>grand mal</em> seizures in 1 patient. Grade ≤ 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%. 1 patient with squamous cell carcinoma achieved a partial response lasting 5 months. Further testing in this and other tumour types using multiple daily schedules is warranted.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90427-F","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of good-risk disseminated non-seminomatous germ cell tumours: the less bleomycin, the more cisplatin?","authors":"S. Culine,&nbsp;M. Mahjoubi,&nbsp;I. Philippot,&nbsp;J.P. Droz","doi":"10.1016/0277-5379(91)90458-P","DOIUrl":"10.1016/0277-5379(91)90458-P","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90458-P","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12887729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiosurgery for brain tumours","authors":"Michael Brada","doi":"10.1016/0277-5379(91)90411-6","DOIUrl":"10.1016/0277-5379(91)90411-6","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90411-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12943910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma","authors":"Mark A. Rosenthal ,&nbsp;Colin A. Bull ,&nbsp;Alan S. Coates ,&nbsp;Graham Stevens ,&nbsp;W.H. McCarthy ,&nbsp;H. Mameghan ,&nbsp;Richard F. Kefford","doi":"10.1016/0277-5379(91)90416-B","DOIUrl":"10.1016/0277-5379(91)90416-B","url":null,"abstract":"<div><p>In two pilot studies, 55 patients with symptomatic metastases from malignant melanoma were treated with irradiation and concurrent cisplatin. In the first group, cisplatin was given as a continuous intravenous infusion of 20 mg/m² per day on days 1–5 and 22–26, with irradiation on days 2, 5, 9, 16, 23 and 26. The second group received 20 mg cisplatin over 24 h commencing 1 h before each fraction of irradiation on days 1, 4, 8, 11, 15 and 18. The first series of 28 patients had 30 lesions treated. Nine (30%) of these lesions responded completely and 10 (33%) achieved partial response for an overall response rate of 63% (95% confidence interval 44–80%). Survival was not evaluated in this group. The second group was comprised of 27 patients, with one irradiated lesion each. 1 patient achieved a complete response and 13 (48%) a partial response for an overall response rate of 52% (32–71%). Median survival was 21 weeks (16–31 weeks). Treatment was well tolerated with nausea and vomiting being the most common toxicity. Synchronous cisplatin infusion with radiotherapy achieves high response rates in metastatic melanoma. Whether it is superior to radiotherapy alone will require evaluation in a randomised trial.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90416-B","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12943915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limb function following conservation treatment of adult soft tissue sarcoma","authors":"Martin H. Robinson ,&nbsp;Louise Spruce ,&nbsp;Ros Eeles ,&nbsp;Ian Fryatt ,&nbsp;Clive L. Harmer ,&nbsp;J.Meirion Thomas ,&nbsp;G. Westbury","doi":"10.1016/0277-5379(91)90417-C","DOIUrl":"10.1016/0277-5379(91)90417-C","url":null,"abstract":"<div><p>Quality of life and limb function were studied in 54 patients who were disease-free 2 or more years after limb-conserving treatment for soft tissue sarcoma of the leg or pelvic girdle. Tumours of the thigh predominated (25 patients) and the mean tumour size was 9.9 cm. 41 patients had been treated with a combination of surgery and radiotherapy (29 with conventional and 12 with high dose), 12 with surgery alone and one with irradiation and intra-arterial doxorubicin. Only 15 patients had a normal range of movement in all lower limb joints and only 12 had normal power in all muscle groups; tumours of the lower leg were particularly unfavourable in this respect. Gait was normal in 42 patients but 8 required a walking aid and 4 a joint support. 16 had detectable lymphoedema but only 2 needed to wear compression hosiery. 35 patients still experienced pain at some time but only 6 required analgesia. However, when assessed by questionnaire for locomotion, grooming and home/leisure/vocational activities, 37 patients (68%) reported excellent function, and only 2 had moderate impairment. Function loss was most marked in leisure (25 patients) and vocational (8) activities, but was mild in 66% of cases. Multivariate analysis was carried out to determine the prognostic factors for poor limb function. The results suggested that overall functional score was predominantly determined by gait (<em>P</em> &lt; 0.001), muscle power or range of movement (<em>P</em> &lt; 0.001), with increasing age, female sex and the use of radiotherapy poor prognostic factors. Reduced muscle power or range of movement were the major factors determining gait (<em>P</em> &lt; 0.02) with the use of radiotherapy the significant prognostic factor for both in the conventionally treated group. Doses in excess of 60 Gy resulted in increased fibrosis and a worse functional outcome. Extent of surgery was not an independent prognostic factor for limb function, although univariate analysis suggested an association with range of movement in the conventionally treated group (<em>P</em> &lt; 0.025). Despite significant objective loss of range of movement and muscle power patients retain excellent limb function and quality of life following limb conserving treatment. For optimal function, radiotherapy should be given with small fractions to a dose not exceeding 60 Gy.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90417-C","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12943916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute megakaryoblastic leukaemia in a child","authors":"Filippo Russo ,&nbsp;Francesco Buda ,&nbsp;Concetta Buda ,&nbsp;Pietro Aragona ,&nbsp;Giovanni Tessitori ,&nbsp;Giorgio Simon ,&nbsp;Sergio Chillemi ,&nbsp;Nicola Caristi ,&nbsp;Alfonso Faiella","doi":"10.1016/0277-5379(91)90457-O","DOIUrl":"10.1016/0277-5379(91)90457-O","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90457-O","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parathyroid hormone-related protein(50–69) and response to pamidronate therapy for tumour-induced hypercalcaemia","authors":"D.J. Dodwell ,&nbsp;S.K. Abbas ,&nbsp;A.R. Morton ,&nbsp;A. Howell","doi":"10.1016/0277-5379(91)90431-C","DOIUrl":"10.1016/0277-5379(91)90431-C","url":null,"abstract":"<div><p>A region-specific radioimmunoassay has been employed to measure levels of immunoreactive parathyroid hormone-related protein^(50–69) (iPTHrP^(50–69)) in patients with tumour-induced hypercalcaemia (TIH). This assay is based on an antiserum raised against synthetic human PTHrP^(50–69). The assay showed no cross-reactivity with human or bovine parathyroid hormone^(1–84). The effect of a single dose (60 mg) of pamidronate was studied in 25 consecutive patients with TIH. All were rehydrated prior to treatment. All but 2 patients (8%) became normocalcaemic after treatment; both of these had very high levels of iPTHrP^(50–69). Time to achieve normocalcaemia, as an index of relative resistance to pamidronate, correlated positively with pretreatment level of iPTHrP^(50–69). Absence of radiological evidence of bone metastases also predicted relative resistance to pamidronate. In this study, iPTHrP^(50–69)-induced osteoclastic bone resorption was a more important mechanism in the causation of TIH than PTHrP-induced renal reabsorption of calcium as assessed by the renal thresholds for calcium and phosphate.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90431-C","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12945229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma","authors":"Mikael J. Kajanti,&nbsp;Seppo O. Pyrhönen","doi":"10.1016/0277-5379(91)90428-G","DOIUrl":"10.1016/0277-5379(91)90428-G","url":null,"abstract":"<div><p>Between August 1986 and September 1990, 22 previously untreated non-cirrhotic patients with measurable unresectable primary liver cancer were treated every 4 weeks with a combination of epirubicin and 5-fluorouracil. The dose of epirubicin was escalated; the starting dose was 40 mg/m², the second dose was 50 mg/m² and thereafter 60 mg/m² during subsequent cycles. The dose of 5-fluorouracil was always 800 mg/m². Objective response rate was 14%. Most of the patients experienced only mild haematological toxicity, and no other dose limiting toxicity was observed. Nonetheless, increasing the dose would probably not have increased the response rate.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90428-G","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III","authors":"Magnus Björkholm,&nbsp;Myeloma Group of Central Sweden","doi":"10.1016/0277-5379(91)90574-W","DOIUrl":"10.1016/0277-5379(91)90574-W","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90574-W","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha interferon in patients with progressive and/or recurrent Hodgkin's disease","authors":"Benjamin Koziner","doi":"10.1016/0277-5379(91)90582-X","DOIUrl":"10.1016/0277-5379(91)90582-X","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90582-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}